InRange publication
InRange diabetes type 1
CGM-based Time-in-Range Using Insuln Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Type 1 Diabetes: The Head-to-Head Randomized Controlled in Range Trial
Tadej Battelino MD, PhD,Thomas Danne MD,Steve V Edelman MD,Pratik Choudhary MD,Eric Renard MD,Jukka Westerbacka MD, PhD,Bhaswati Mukherjee MD,Valerie Pilorget MD,Mathieu Coudert MSc,Richard M Bergenstal MD
Diabetes Obes Metab. 2022; 1- 11. doi:10.1111/dom.14898
See the result of the InRange study here
Learn more about TiR, the study
design and result of InRange
Relaterade Artiklar
Lucas Received Four Diagnoses at Once: “30,000 Emotions Rushed Through Me”
Being diagnosed with type 1 diabetes at the age of 18 is a life-altering experience for most people. But when, like Lucas, you receive three other diagnoses within a few months, it can feel overwhelming. Living with type 1 diabetes becomes even more challenging when you also have autism.
Diagnosing Type 1 Diabetes in Kids: A Family's Story
Three years ago, Tina’s 13-year-old son was diagnosed with type 1 diabetes. It was a harrowing ordeal, as he was rushed to the hospital with severe diabetic ketoacidosis. Even today, the entire family remains deeply affected by the traumatic experience.
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!
Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4
SE-FILMEN-HÄR
